Reprising this from my AEI colleague Ben Ippolito on the cost of Medicare coverage for GLP-1s. CMS appears to see writing on wall here: As additional indications are approved, most Medicare recipients will get coverage for other co-morbidities. Also, Semaglutide subject to IRA price controls in 2027
1 / 4
Comments